Home
BCDA
BCDA News

Latest BioCardia Inc. (BCDA) News on December 19, 2024

BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family

GlobeNewswire

2 days ago

BioCardia Announces Commercial Availability of Morph® DNA™ Steerable Introducer Product Family

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

GlobeNewswire

14 days ago

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

BioCardia Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023)

Simply Wall St.

a month ago

BioCardia Third Quarter 2024 Earnings: US$0.61 loss per share (vs US$1.79 loss in 3Q 2023)

BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ...

GuruFocus.com

a month ago

BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ...

BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results

GlobeNewswire

a month ago

BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results

BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024

GlobeNewswire

a month ago

BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024

BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

GlobeNewswire

2 months ago

BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure

BioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

GuruFocus.com

2 months ago

BioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

MT Newswires

3 months ago

BioCardia Regains Compliance with Nasdaq Listing Rules for Minimum Equity Levels

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

GlobeNewswire

3 months ago

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire

3 months ago

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

MT Newswires

4 months ago

BioCardia Prices $7.2 Million Public Offering

BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire

4 months ago

BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

MT Newswires

4 months ago

Top Midday Gainers

MT Newswires

4 months ago

Sector Update: Health Care Stocks Advance Premarket Thursday

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

GlobeNewswire

4 months ago

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

MT Newswires

4 months ago

Top Premarket Gainers

MT Newswires

4 months ago

BioCardia Says FDA Cleared Morph DNA Steerable Introducer; Shares Soar Pre-Bell

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

GlobeNewswire

4 months ago

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

GlobeNewswire

4 months ago

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024

GlobeNewswire

4 months ago

BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024

BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product Family

GlobeNewswire

5 months ago

BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product Family

Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure

GlobeNewswire

5 months ago

Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure

MT Newswires

5 months ago

BioCardia Receives Patent for Morph DNA Transseptal Delivery

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

GlobeNewswire

5 months ago

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction

GlobeNewswire

5 months ago

CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction

MT Newswires

6 months ago

Top Premarket Decliners

MT Newswires

6 months ago

BioCardia Receives Patent for Transendocardial Biotherapeutic Delivery Catheter; Shares Rise Pre-Bell

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

GlobeNewswire

6 months ago

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

Getting smarter: FIA Launches 3-Day Smart Driving Challenge in Samarkand, Powered by Greater Than

PR Newswire

6 months ago

Getting smarter: FIA Launches 3-Day Smart Driving Challenge in Samarkand, Powered by Greater Than

3 Major Product Releases at 3Shape Discover Event

PR Newswire

6 months ago

3 Major Product Releases at 3Shape Discover Event

GlobeNewswire

6 months ago

Fiber Optic Sensors Global Market Forecast & Analysis 2023-2033: Global Fiber Optic Sensors Market to Reach $605.4 Million by 2032 with a CAGR of 6.2%

Simply Wall St.

6 months ago

Exploring SEHK Growth Companies With High Insider Ownership: BYD Leads The Way

Business Wire

6 months ago

Net Asset Value(s)

AFP

6 months ago

Irish, Czechs hold EU vote after Dutch far-right gains

Motley Fool

6 months ago

Trade the Nvidia Stock Split? The Tried-and-True Method to Make the Best Profits on the Leading AI Stock

GlobeNewswire

6 months ago

GPRC5D Targeting Drugs Market Opportunity and Clinical Trials Insight 2024: Insight on 15+ Drugs in Clinical Trials

MT Newswires

7 months ago

BioCardia to Implement 1-for-15 Reverse Stock Split; Shares Fall After Hours

BioCardia Announces Reverse Stock Split

GlobeNewswire

7 months ago

BioCardia Announces Reverse Stock Split

GuruFocus.com

7 months ago

BioCardia Inc (BCDA) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress Amid ...

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

GlobeNewswire

7 months ago

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is Reasonable

Simply Wall St.

7 months ago

Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is Reasonable

BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024

GlobeNewswire

7 months ago

BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024

BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

GlobeNewswire

8 months ago

BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

GlobeNewswire

8 months ago

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

Insiders Are Buying These 11 Penny Stocks

Insider Monkey

9 months ago

Insiders Are Buying These 11 Penny Stocks

BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript

Insider Monkey

9 months ago

BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript

BioCardia Full Year 2023 Earnings: Misses Expectations

Simply Wall St.

9 months ago

BioCardia Full Year 2023 Earnings: Misses Expectations

Thomson Reuters StreetEvents

9 months ago

Q4 2023 BioCardia Inc Earnings Call

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

GlobeNewswire

9 months ago

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

GlobeNewswire

9 months ago

BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

GlobeNewswire

9 months ago

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

GlobeNewswire

9 months ago

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

GlobeNewswire

9 months ago

BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

GlobeNewswire

10 months ago

BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

iCoreConnect Announces Exciting Updates to One of Its Leading SaaS Solutions

NewMediaWire

a year ago

iCoreConnect Announces Exciting Updates to One of Its Leading SaaS Solutions

BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference

GlobeNewswire

a year ago

BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference

Worksport Subsidiary Terravis Energy Starts To Build Heat Pump Supply Chain

GlobeNewswire

a year ago

Worksport Subsidiary Terravis Energy Starts To Build Heat Pump Supply Chain

Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference

PR Newswire

a year ago

Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference

SEALSQ SEALCOIN: A Game Changer in Machine-to-Machine Economy

GlobeNewswire

a year ago

SEALSQ SEALCOIN: A Game Changer in Machine-to-Machine Economy

Worksport Announces Expansion of B2B Dealer Network and Upcoming Availability on Amazon, eBay, Walmart Marketplaces

GlobeNewswire

a year ago

Worksport Announces Expansion of B2B Dealer Network and Upcoming Availability on Amazon, eBay, Walmart Marketplaces

REE Ships P7-C Demo to FMI Truck Sales & Service; Franz Bakery, Bedmart, Indoor Billboard, PointS Tires and Kelly’s Home Center Fleets Set to Begin Evaluation of P7-C Vehicle

GlobeNewswire

a year ago

REE Ships P7-C Demo to FMI Truck Sales & Service; Franz Bakery, Bedmart, Indoor Billboard, PointS Tires and Kelly’s Home Center Fleets Set to Begin Evaluation of P7-C Vehicle

Gamida Cell Actively Pursuing Strategic Alternatives

GlobeNewswire

a year ago

Gamida Cell Actively Pursuing Strategic Alternatives

2024 Promises An EV Evolution With New Clean Energy Solutions

Benzinga

a year ago

2024 Promises An EV Evolution With New Clean Energy Solutions

SU Group Holdings Limited Announces Closing of Initial Public Offering

PR Newswire

a year ago

SU Group Holdings Limited Announces Closing of Initial Public Offering

Pro-Dex (NASDAQ:PDEX) shareholders have earned a 7.2% CAGR over the last five years

Simply Wall St.

a year ago

Pro-Dex (NASDAQ:PDEX) shareholders have earned a 7.2% CAGR over the last five years

PepperLime Health Acquisition Corporation Announces Plan to Liquidate

ACCESSWIRE

a year ago

PepperLime Health Acquisition Corporation Announces Plan to Liquidate

RF Industries, Ltd. (NASDAQ:RFIL) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

RF Industries, Ltd. (NASDAQ:RFIL) Q4 2023 Earnings Call Transcript

Phoenix to Hold Update Webcast/Conference Call Following the Purchase of Proterra's Transit Business

ACCESSWIRE

a year ago

Phoenix to Hold Update Webcast/Conference Call Following the Purchase of Proterra's Transit Business

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 01/25/2024

Genius Group and FatBrain AI Agree to Merge into Growth Platform to Accelerate the Exponential Economy of Tomorrow

GlobeNewswire

a year ago

Genius Group and FatBrain AI Agree to Merge into Growth Platform to Accelerate the Exponential Economy of Tomorrow

A2Z Secures Initial Purchase Order for 500 Smart Carts in Belgium

ACCESSWIRE

a year ago

A2Z Secures Initial Purchase Order for 500 Smart Carts in Belgium

Argus Research

a year ago

Daily – Vickers Top Insider Picks for 01/24/2024

MAQUIA CAPITAL ACQUISITION CORPORATION ANNOUNCES SPONSOR MONTHLY CONTRIBUTION OF 2.5% ADDITIONAL FOUNDER SHARES FOR EXTENSION AMENDMENT

GlobeNewswire

a year ago

MAQUIA CAPITAL ACQUISITION CORPORATION ANNOUNCES SPONSOR MONTHLY CONTRIBUTION OF 2.5% ADDITIONAL FOUNDER SHARES FOR EXTENSION AMENDMENT

AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer

GlobeNewswire

a year ago

AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer

Genius Group 2024 Financial Guidance: 110% Growth to $56m - $60m Revenue with Positive EBITDA

GlobeNewswire

a year ago

Genius Group 2024 Financial Guidance: 110% Growth to $56m - $60m Revenue with Positive EBITDA

$Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient$

GlobeNewswire

a year ago

Cellectar Biosciences Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

GlobeNewswire

a year ago

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

Phoenix Issues Preliminary Guidance Following the Purchase of Proterra's Transit Business

ACCESSWIRE

a year ago

Phoenix Issues Preliminary Guidance Following the Purchase of Proterra's Transit Business

Shanchun Huang Responds to SEC Allegations

PR Newswire

a year ago

Shanchun Huang Responds to SEC Allegations

Future FinTech Responds to Inquiry of CEO

PR Newswire

a year ago

Future FinTech Responds to Inquiry of CEO

Avino’s Q4 and Full Year 2023 Production Results

ACCESSWIRE

a year ago

Avino’s Q4 and Full Year 2023 Production Results

Natural Grocers® Invites Customers to Annual Resolution Reset Event, January 16-20, 2024

PR Newswire

a year ago

Natural Grocers® Invites Customers to Annual Resolution Reset Event, January 16-20, 2024

Phoenix Completes Purchase of Proterra's Transit Business

ACCESSWIRE

a year ago

Phoenix Completes Purchase of Proterra's Transit Business

Natural Grocers® Honors Martin Luther King Jr. Day, 2024 with Annual In-store Fundraiser to Jack and Jill of America Foundation

PR Newswire

a year ago

Natural Grocers® Honors Martin Luther King Jr. Day, 2024 with Annual In-store Fundraiser to Jack and Jill of America Foundation

Newsfile

a year ago

Snow Lake Lithium CEO Update to Shareholders

abrdn U.S. Closed End Funds Announce Distribution Payment Details

ACCESSWIRE

a year ago

abrdn U.S. Closed End Funds Announce Distribution Payment Details

SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate

Zacks

a year ago

SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

GlobeNewswire

a year ago

AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

Airgain Announces AirgainConnect™ Fleet: an Innovative Roof-Mounted 5G Vehicle Gateway

Business Wire

a year ago

Airgain Announces AirgainConnect™ Fleet: an Innovative Roof-Mounted 5G Vehicle Gateway

Culp Announces Leadership Addition at Culp Upholstery Fabrics, Along With Planned Transition for Division President Boyd Chumbley

Business Wire

a year ago

Culp Announces Leadership Addition at Culp Upholstery Fabrics, Along With Planned Transition for Division President Boyd Chumbley

DermTech Announces Positive Topline Results From Trust 2 Study Evaluating the DermTech Melanoma Test (DMT)

Business Wire

a year ago

DermTech Announces Positive Topline Results From Trust 2 Study Evaluating the DermTech Melanoma Test (DMT)

Business Wire

a year ago

AIM Shareholders Elect All Four Company Director Nominees at 2023 Annual Meeting

Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance

Business Wire

a year ago

Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance

Upexi CEO, Allan Marshall, to Present at the iAccess Alpha 2024 Buyside Best Ideas Summit on January 9th & 10th

ACCESSWIRE

a year ago

Upexi CEO, Allan Marshall, to Present at the iAccess Alpha 2024 Buyside Best Ideas Summit on January 9th & 10th

Kellner Seeking Expedited Appeal of Delaware Court Finding that Nomination Notice was Properly Denied

PR Newswire

a year ago

Kellner Seeking Expedited Appeal of Delaware Court Finding that Nomination Notice was Properly Denied

BurgerFi to Participate in the 26th Annual ICR Conference

GlobeNewswire

a year ago

BurgerFi to Participate in the 26th Annual ICR Conference

BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders

GlobeNewswire

a year ago

BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders

Positive Signs As Multiple Insiders Buy BioCardia Stock

Simply Wall St.

a year ago

Positive Signs As Multiple Insiders Buy BioCardia Stock

Estimating The Intrinsic Value Of Airgain, Inc. (NASDAQ:AIRG)

Simply Wall St.

a year ago

Estimating The Intrinsic Value Of Airgain, Inc. (NASDAQ:AIRG)

Share on Social Networks: